Tag: Pfizers

Categories
Health

U.S. Officers Push Again on Pfizer’s Request for Booster Shot Approval

U.S. Officials Push Back on Pfizer’s Request for Booster Shot Approval

Pfizer officials met privately with senior U.S. scientists and regulators on Monday to press for rapid approval of booster coronavirus vaccines amid growing public confusion over whether they are needed and opposition from federal health officials who say that the additional doses are now not required.

The high-level online meeting, which lasted an hour, and at which Pfizer’s chief scientist briefed virtually every top doctor in the federal government, took place the same day Israel began feeding heart transplant patients and others on the third dose of the Pfizer BioNTech vaccine administer weakened immune system. Officials said after the meeting that more data – and possibly several months – would be needed before regulators could determine whether booster injections were needed.

The two developments underscored the intensifying debate about whether booster injections are required in the US, when and for whom. Many American experts, including Dr. Anthony S. Fauci, President Biden’s senior medical advisor on the pandemic, have said there isn’t enough evidence yet that boosters are necessary. However, some say Israel’s move may anticipate a government decision to recommend it to at least the weak.

Pfizer is collecting information on antibody responses from those receiving a third dose, as well as data from Israel, and expects to share at least part of that in a formal application to the Food and Drug Administration for its coronavirus vaccine to expand its emergency clearance in the coming weeks.

However, the final decision on booster vaccination, several officials said after the meeting, will also depend on real-world information the Centers for Disease Control and Prevention has gathered about breakthrough infections – those that occur in people who have been vaccinated – who are serious or ill Cause hospital stays.

And any booster vaccination recommendations are likely to be calibrated within age groups as well, officials said. For example, if booster shots are recommended, they could first go to residents of nursing homes who received their vaccines in late 2020 or early 2021, while older people who received their first vaccinations in the spring may have to wait longer. And then the question arises, what kind of booster: a third dose of the original vaccine or perhaps a vaccination tailored to the highly contagious Delta variant, which is on the rise in the USA.

“It was an interesting meeting. They shared their data. There was nothing like a decision, ”said Dr. Fauci in a short interview Monday night, adding, “This is just part of a much bigger puzzle, and it’s part of the data, so there’s no question of a compelling case either way.”

Amy Rose, a Pfizer spokeswoman, said in a statement, “We had a productive meeting with US public health officials about elements of our research program and preliminary booster data.”

The Ministry of Health and Welfare, which convened the meeting, issued its own statement confirming the government’s stance. “At this point, fully vaccinated Americans don’t need a booster dose,” it said.

With less than half of the United States’ population being fully vaccinated, some experts said Monday the country must continue to focus on giving all Americans their first dose. The most important task of the Food and Drug Administration is to increase public confidence by granting full approval to the coronavirus vaccines used, which are initially approved in an emergency.

“At this point the most important strengthening we need is vaccinating people,” said Dr. Carlos del Rio, an infectious disease expert at Emory University in Atlanta. The booster doses in Israel, he added, “will help us answer some questions, but at the end of the day I disagree with what they are doing. I think it’s terribly premature. “

Within the Biden government, some fear that if Americans are convinced that coronavirus vaccines only offer short-lived immunity before needing a boost, they are less likely to accept vaccination. Those concerns could fall by the wayside, however, if new data from Israel, expected in the next few weeks, conclusively shows that immunity wears off after six to eight months, significantly increasing the risks for the elderly or other vulnerable populations.

The government convened the meeting on Monday in response to the announcement last week by Pfizer and its German partner BioNTech that they would develop a version of their vaccine targeting the Delta variant and reported promising results from studies with people who A third dose of the vaccine received original vaccine six months after the second.

The new dates Not yet published or peer-reviewed, but as announced by companies that they would submit data to the Food and Drug Administration to approve booster vaccinations surprised the Biden White House.

In an unusual joint statement Thursday evening, hours after Pfizer-BioNTech’s announcement, the FDA and CDC pushed back.

“Americans who are fully vaccinated currently do not need a booster,” the statement said, adding, “We are prepared for booster doses when and when science shows they are needed.”

The move can make economic sense for Pfizer-BioNTech. Since the outbreak of the pandemic, the partner companies have been following a “get to market first” strategy in the manufacture and marketing of their vaccines.

The companies did not accept federal funds or participate in Operation Warp Speed, former President Donald J. Trump’s fast-track vaccine initiative. Not only were they the first to get Food and Drug Administration approval for their coronavirus vaccine, the first to use the novel mRNA technology, but also the first to get their vaccine approved in adolescents.

The strategy has “paid off as well as you could wish,” said Steve Brozak, president of WBB Securities, a biotechnology-focused research investment bank.

Last week, Pfizer and BioNTech said a booster given six months after the second dose of the vaccine increased the effectiveness of antibodies against the original virus and beta variant by five to ten times. But antibody levels may not be the best biological measure of need for booster doses, say experts, who say it’s no surprise that antibodies increase after a third dose.

“The antibody response is not the only measure of immune protection,” said Dr. Leana S. Wen, a former health commissioner for Baltimore. “There have been several studies to suggest that these vaccines also stimulate B-cell and T-cell immunity. Even if there aren’t that many antibodies, it doesn’t mean someone isn’t protected. “

In Israel, the government has agreed to provide Pfizer with data on its vaccine recipients, and Pfizer has cross-checked the Israeli data with the results of its own laboratory tests. Some people familiar with the data say this suggests that those vaccinated may lose immunity after about six to eight months, leading to an increasing number of breakthrough infections.

The participants in Monday’s meeting were a who’s who of government doctors: Dr. Fauci; Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention; Dr. Francis Collins, the director of the National Institutes of Health; Dr. Vivek Murthy, the general surgeon; Dr. Rachel Levine, the assistant secretary of health; Dr. Janet Woodcock, acting FDA commissioner; Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research; and Dr. David Kessler, a former FDA commissioner who, among other things, leads the Biden government’s vaccine distribution efforts.

Dr. Del Rio, of Emory University, complained that the meeting was held privately on Monday instead of Pfizer publicly presenting its dates to the CDC’s Advisory Committee on Vaccine Practices, which will ultimately recommend whether booster injections are needed.

Just over two-thirds of American adults – 67.7 percent – got at least one Covid-19 shot, according to the CDC. The president had hoped to have at least partially vaccinated 70 percent of adults by July 4th.

Still, the national vaccination campaign has made it clear that the vaccine is successful in preventing disease, and studies suggest that vaccines against the Delta variant remain effective. Outbreaks occur in areas with low vaccination rates and the number of national cases has increased recently; according to a database from the New York Times.

World Health Organization officials on Monday stressed the importance of prioritizing global vaccine production and distribution over booster development, given the large gaps between countries’ vaccine programs.

“That doesn’t mean one or the other; it brings order to a crisis, ”said Dr. Michael Ryan, the organisation’s executive director of the emergency health program, on what the organization calls a two-stage pandemic.

Lauren McCarthy contributed to the coverage.

Categories
Health

Charts present how Pfizer’s vaccine is working

UK hospitals use blockchain to track coronavirus vaccine temperature

1.8 ml sodium chloride is added to a vial of Pfizer / BioNTech COVID-19 vaccine concentrate ready for administration at Guy’s Hospital at the start of the largest vaccination program in UK history on December 8, 2020 in London, UK.

Victoria Jones – Pool | Getty Images

LONDON – New data from England has shown how effective coronavirus vaccines are in fighting the disease, even after just one dose.

In December, the vaccine developed by Pfizer and BioNTech became the first vaccine to be approved and launched in the UK

The elderly, health workers and nursing home workers were the first to be vaccinated. This was soon followed by the shot developed by the British company AstraZeneca and the University of Oxford, another vaccine that requires two doses.

Infection control

Figures in a research report by Public Health England released Monday, but pending peer review, showed Pfizer and Oxford-AstraZeneca vaccines are highly effective in reducing Covid infections in people aged 70 and over.

Since the study began in January, protection against symptomatic Covid four weeks after the first dose has ranged between 57% and 61% for the Pfizer vaccine and between 60% and 73% for the AstraZeneca vaccine.

The effectiveness of the vaccine in the data for Public Health England is calculated using a mathematical ratio. Click here for full data and methods.

Reduce hospital stays and deaths

The study, which included data from over 7.5 million people, also found that a single dose offered additional protection against hospitalizations and death.

It is said that coronavirus cases in vaccinated people had about half the risk of severe outcomes compared to non-vaccinated cases. It combined this with estimates of their effectiveness against symptomatic disease and predicted that a single dose of either vaccine would be about 80% effective in preventing hospitalization in the elderly about three to four weeks after the first dose.

It has also been suggested that a single dose of the Pfizer vaccine is 85% effective in preventing death from Covid-19 in those over 80.

British Health Secretary Matt Hancock called the results “very strong”.

“They could also help explain why the number of Covid ICU admissions for people over 80 in the UK has dropped to single digits in recent weeks,” he said.

UK policymakers feel vindicated after deciding to postpone the second dose to around three months in order to vaccinate more people with a first dose faster. Experts in the US hesitated with the strategy, and White House chief medical officer Dr. Anthony Fauci said Monday that “there are risks on both sides”.

As of Sunday, 20,275,451 Brits have received their first dose of vaccine and 815,816 have received both doses, government data said.

The UK vaccination program was widely hailed as a triumph amid tragedy. The UK has the fifth highest number of infections in the world after the US, India, Brazil and Russia, with nearly 4.2 million infections and over 123,000 deaths. This is the fifth highest number of deaths in the world, according to Johns Hopkins University.

—CNBC’s Bryn Bache contributed to this article.

Explanation: This story has been updated to better reflect the vaccine effectiveness calculations.

Categories
Health

Dr. Scott Gottlieb on Pfizer’s efforts on a 3rd Covid vaccine shot

Dr. Scott Gottlieb on Pfizer's efforts on a third Covid vaccine shot

Pfizer board member Dr. Scott Gottlieb told CNBC on Thursday that the company is researching two different methods to provide vaccination protection against new coronavirus variants.

In an interview on Squawk Box, Gottlieb said the first approach focused on whether a booster shot using the current formulation of the two-dose vaccine would provide additional defense. Pfizer and its German partner BioNTech announced a test that was not examined until early Thursday.

“There is reason to believe that just boosting the existing vaccine against these new variants will give you extra protection,” said Gottlieb, a former Food and Drug Administration commissioner in the Trump administration.

The second endeavor is to modify the existing vaccine so that stronger immunity to virus mutations can be achieved, explained Gottlieb. The companies announced in a press release on Thursday that they are discussing the launch of this research study with regulators.

While new coronavirus variants affect public health officials, particularly the contagious strain first found in South Africa, Gottlieb said any change to the vaccine formulation would offer broad protection.

“What you want to do is not necessarily develop a vaccine that is specifically against [B.1.351], the change we’ve seen in South Africa, “said Gottlieb, who headed the FDA from 2017-2019.” You want to develop a protein sequence that is sort of a consensus sequence and that incorporates enough of the changes we’ve seen around the world that you have a vaccine that protects no matter what the virus does against itself. “

It is widely believed that the virus variant discovered in South Africa poses a greater challenge to existing vaccines than other new strains, such as the one originally discovered in the UK

For example, Johnson & Johnson reported that their vaccine was 72% effective in preventing symptomatic Covid in the US and 57% in South Africa, where the B.1.351 strain dominates. However, the vaccine provided 85% protection against severe Covid throughout the trial. Part of this has also been carried out in regions of Latin America where different variants exist.

The U.S. FDA is expected to use J & J’s vaccine soon after the agency’s emergency vaccine board meeting scheduled for Friday.

Pfizer-BioNTech and Moderna vaccines, which already have an emergency approval in the US, were tested in large phase three studies before the new variants were discovered. However, Pfizer and BioNTech conducted a study examining the variant found in South Africa. This indicated some reduction in antibody production, even though the vaccine was still neutralizing the virus.

In addition, Moderna has said that its two-dose vaccine appears to produce a weaker immune response against the South African variant, while adding that the antibody response remains at levels believed to provide protection.

Moderna announced Wednesday that it has shipped an optimized version of its vaccine to the National Institutes of Health to start various studies on variant protection. Similar to Pfizer, the company will also be testing a lower-dose booster shot of its current two-dose formulation.

Limited available doses have been a barrier to covid shots being given to more people once government approval has been granted. In the U.S. in particular, that situation has improved as companies ramp up production, and Gottlieb noted that J & J’s possible approval of the single-dose vaccine will also help expand access.

Should a booster shot be needed to ensure better protection against variants, Gottlieb was confident that the dosage might be available. “I don’t think we have to ration supplies if we want to give people a third booster in the fall,” he said.

“The challenge will be to think about the new vaccine variant and whether and when you would switch to this vaccine and how much you would produce,” said Gottlieb. “That will be a decision you need to make before these new variants of vaccines are likely to get approved. You may not want to switch all of your manufacturing, but you want to switch some of it.” He added, “You will likely have to make that decision sometime this summer.”

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, healthcare technology company Aetion, and biotech company Illumina. He is also co-chair of the Healthy Sail Panel of Norwegian Cruise Line Holdings and Royal Caribbean.

Categories
Health

Well being Care Employee Had Critical Allergic Response After Pfizer’s Covid Vaccine

Health Care Worker Had Serious Allergic Reaction After Pfizer's Covid Vaccine

WASHINGTON – Two health care workers at the same Alaska hospital developed reactions just minutes after receiving the coronavirus vaccine from Pfizer this week, including a worker who was supposed to stay in the hospital until Thursday.

Health officials said the cases would not disrupt their plans to launch vaccines and that they would share the information for the sake of transparency.

The first worker, a middle-aged woman with no history of allergies, had an anaphylactic reaction that began 10 minutes after receiving the vaccine at the Bartlett Regional Hospital in Juneau on Tuesday, a hospital official said. She had a rash over her face and trunk, shortness of breath, and an increased heart rate.

Dr. Lindy Jones, the hospital’s emergency room medical director, said the worker was first given a shot of adrenaline, a standard treatment for severe allergic reactions. Her symptoms subsided, but then came back and she was treated with steroids and an adrenaline drop.

When the doctors tried to stop the drip, her symptoms reappeared, so the woman was taken to the intensive care unit, which was observed all night, and then taken off the drip early Wednesday morning, Dr. Jones.

Dr. Jones had said earlier Wednesday that the woman should be discharged that evening, but the hospital said late Wednesday that she would be staying one more night.

The second worker received his shot Wednesday and developed eye swelling, lightheadedness and a sore throat 10 minutes after the injection, the hospital said in a statement. He was taken to the emergency room and treated with adrenaline, Pepcid, and Benadryl, though the hospital said the reaction wasn’t anaphylaxis. The worker was back to normal within an hour and was released.

The hospital, which had given a total of 144 doses on Wednesday night, said both workers didn’t want their experience to negatively impact others who line up for the vaccine.

“We have no plans to change our vaccination schedule, dosage, or treatment regimen,” said Dr. Anne Zink, Alaska’s chief medical officer, in a statement.

Although the Pfizer vaccine was shown to be safe and 95 percent effective in a clinical trial of 44,000 participants, the Alaska cases are likely to heighten concerns about possible side effects. Experts said developments could lead to calls for stricter guidelines to ensure recipients were carefully monitored for side effects.

Dr. Paul A. Offit, a vaccine expert and a member of an outside advisory panel that recommended the Food and Drug Administration approve Pfizer’s emergency vaccine, said the appropriate precautions have already been taken. For example, he said, requiring recipients to remain in place for 15 minutes after receiving the vaccine helped ensure that the woman was treated quickly.

“I don’t think this means we should take a break,” he said. “Not at all.” But he said the researchers need to find out “which component of the vaccine is causing this response”.

Dr. Jay Butler, a leading infectious disease expert with the Centers for Disease Control and Prevention, said the situation in Alaska showed that the surveillance system was working. The agency has recommended that the vaccine be given in environments where oxygen and adrenaline are available to treat anaphylactic reactions.

Millions of Americans are expected to be vaccinated with the Pfizer vaccine by the end of the year. As of Wednesday evening, it was unclear how many Americans had received it so far. Alex M. Azar II, the secretary for health and human services, said his department would release these data “several days or maybe a week later.”

The Alaska woman’s response was believed to be similar to the anaphylactic reactions two health workers in the UK had after receiving the Pfizer BioNTech vaccine last week. How they both recovered.

These cases are expected to occur Thursday, when FDA scientists are due to meet with the agency’s external panel of experts to decide whether regulators should recommend Moderna’s Covid-19 vaccine for the emergency.

Although the Moderna and Pfizer-BioNTech vaccines are based on the same technology and are similar in their ingredients, it is not clear whether an allergic reaction to one vaccine would occur with the other. Both are made up of genetic material called mRNA, which is trapped in a bubble of oily molecules called lipids, although they use different combinations of lipids.

Dr. Offit said the bladders in both vaccines are coated with a stabilizing molecule called polyethylene glycol, which he saw as a “prime candidate” for causing an allergic reaction. He stressed that further research was needed.

Pfizer’s study did not identify serious adverse events from the vaccine, although many participants experienced pain, fever, and other side effects. The Alaskan reactions were thought to be related to the vaccine because they came on so quickly after the shot.

A Pfizer spokeswoman, Jerica Pitts, said the company doesn’t have all the details of the Alaska situation but is working with local health officials. The vaccine contains information that indicates that medical treatment should be available in the event of a rare anaphylactic event, she said. “We will closely monitor any reports suggestive of serious post-vaccination allergic reactions and update the labeling language as necessary,” said Ms. Pitts.

After workers in the UK fell ill, authorities there warned against giving the vaccines to anyone with a history of severe allergic reactions. They later clarified their concerns and changed the wording of “severe allergic reactions” to mean that the vaccine should not be given to anyone who has ever had an anaphylactic reaction to a food, medicine, or vaccine. That type of response to a vaccine is “very rare,” they said.

Pfizer officials said the two Britons who had the reaction had severe allergies in the past. A 49-year-old woman has had egg allergies in the past. The other, a 40-year-old woman, had a history of allergies to several drugs. Both wore EpiPen-like devices to inject adrenaline in the event of such a reaction.

Pfizer has said that its vaccine does not contain egg ingredients.

The UK update also said a third patient had a “possible allergic reaction” but did not describe it.

In the United States, federal regulators on Friday gave adults ages 16 and older full approval for the vaccine. Healthcare providers have been warned not to give the vaccine to anyone with a “known history of a severe allergic reaction” to any component of the vaccine. This is a standard warning for vaccines.

Due to the UK cases, FDA officials have announced that they will require Pfizer to step up surveillance for anaphylaxis and provide data on it once the vaccine continues to be used. Pfizer also said that it was recommended that the vaccine be given in environments with access to anaphylaxis treatment equipment. Last weekend, the CDC said people with severe allergies could be safely vaccinated, with close monitoring 30 minutes after receiving the shot.

Anaphylaxis can be life-threatening, with difficulty breathing and drops in blood pressure that usually occur within minutes or even seconds of contact with a food or drug or even a substance such as latex that the person is allergic to.

Carl Zimmer contributed to the reporting.

Categories
Health

FDA advisory panel meets at this time to vote on whether or not to advocate approval of Pfizer’s Covid vaccine

FDA advisory panel meets today to vote on whether to recommend approval of Pfizer's Covid vaccine

[The stream is slated to start at 9 a.m. ET. Please refresh the page if you do not see a player above at that time.]

A panel from the Food and Drug Administration will meet Thursday to vote on whether to recommend Pfizer and BioNTech’s emergency approval of the coronavirus vaccine.

Prior to voting by the Agency’s Advisory Committee on Vaccines and Related Biological Products, the independent panel of medical experts will evaluate the Pfizer clinical trial data and provide their opinion on the vaccine, including whether the benefits outweigh the risks in an emergency .

The FDA is not required to follow the advice of the advisory group, but it often does.

A recommendation from the advisory committee is the final step before the FDA is likely to give final OK to the distribution of the potentially life-saving doses in the United States. The vaccine would be the first to be approved for use in the United States

Read CNBC’s live updates for the latest news on the Covid-19 outbreak.

Categories
Health

Pfizer’s Covid vaccine permitted by FDA for emergency use

Pfizer's Covid vaccine approved by FDA for emergency use

The Food and Drug Administration has approved Pfizer and BioNTech’s coronavirus vaccine for emergency use. This is a monumental turning point in the one-time pandemic that killed nearly 300,000 Americans and devastated the US economy in less than a year.

FDA chief scientist Denise Hinton told Pfizer in a letter Friday that she approved the company’s emergency use of the vaccine.

President Donald Trump called it a “medical miracle” in a video tweet. “We delivered a safe and effective vaccine in just 9 months,” Trump said. “This is one of the greatest scientific achievements in history.”

Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said the decision “promises to change the course of this pandemic in the United States.” “With the science guiding our decision-making, the available safety and efficacy data to support the approval of the Pfizer-BioNTech COVID-19 vaccine because the known and potential benefits of the vaccine significantly outweigh the known and potential risks,” he said.

FDA approval for the emergency will now boost the federal government’s distribution of the potentially life-saving doses to 64 states, territories and major cities across the country. The government plans to distribute 2.9 million doses of the vaccine within 24 hours, followed by another 2.9 million doses 21 days later, for patients to receive their second shot, General Gustave Perna, who runs the logistics for the Operation Warp vaccination program Speed ​​monitored by President Donald Trump said Wednesday. Pfizer’s vaccine requires two doses three weeks apart.

The vaccine couldn’t come at a more crucial time. Hospitals in the U.S. already have higher numbers of Covid patients than ever before, and the country’s outbreak is poised to break even grimmer records. According to a CNBC analysis of the Johns Hopkins University data, the US reported 3,124 new Covid-19 deaths on Wednesday, the pandemic’s deadliest one-day record to date. The director of the Centers for Disease Control and Prevention, Dr. Robert Redfield, warned earlier this month that the next few months of the pandemic would be “some of the most difficult in the history of this country’s public health.”

Initial doses of the Pfizer vaccine will be limited as production begins. Officials predict it will be months before everyone in the US who wants to be vaccinated is vaccinated. Pfizer has announced that it will ship 50 million doses of vaccine this year, enough to vaccinate 25 million people. The vaccine is expected to be distributed in phases where the most critical U.S. workers and vulnerable people receive it first. The CDC has given states an outline recommending that priority be given to health workers and nursing homes first. However, states may distribute the vaccine at their own discretion.

An emergency permit, or EEA, is not the same as a full permit, which can typically take months. Pfizer has only submitted safety data for two months, but it typically takes the agency six months for full approval. The vaccine has been approved for people aged 16 and over.

On Friday, FDA Commissioner Stephen Hahn said the agency was “working fast” to clear the vaccine in case of emergency. Shortly after Hahn testified, Trump, who has repeatedly said he had urged the FDA to move faster in the vaccine development process, told the agency in a tweet: “Get the dam vaccines out NOW.”

The FDA’s announcement comes after a key agency advisory body voted 17 to 4, with one abstention, to recommend the vaccine for emergency approval on Thursday. The Advisory Committee on Vaccines and Related Biological Products plays a key role in approving influenza and other vaccines in the United States and verifying that the vaccines are safe for public use. While the FDA does not need to follow the advisory board’s recommendation, it often does.

FDA approval marks a record breaking time frame for a process that typically takes about a decade. The fastest vaccine development to date against mumps took more than four years and was licensed in 1967. Pfizer and BioNTech announced plans to develop a coronavirus vaccine in March and filed an emergency clearance application with the FDA in November. Health authorities in Canada, the UK and Bahrain have approved Pfizer’s vaccine for most adults.

Pfizer’s vaccine uses messenger RNA or mRNA technology. It’s a new approach to vaccines that uses genetic material to trigger an immune response. Moderna, another front runner in the Covid vaccine race, also uses mRNA technology. Late-stage clinical trial data shows Pfizer’s vaccine is 95% effective against Covid, safe, and appears to ward off serious illness. For maximum effectiveness, the vaccine requires two doses about 21 days apart.

Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit, which poses potential logistical challenges for rural areas and inner cities that may not have good health infrastructure. For comparison: According to Moderna, the vaccine can be stored for up to six months at minus 4 degrees Fahrenheit.

FedEx and United Parcel Service on Thursday expressed confidence in their networks to distribute the vaccines across the country in a Senate hearing and outlined plans to monitor the location and temperatures of the shipments.

The Federal Aviation Administration asked the airports late Friday to ensure that they have adequate staff when the vaccines arrive. In a statement hours before the vaccine was approved, the FAA said airports should consider providing areas for trucks for vaccines to be picked up on arrival. The agency has announced that flights with cans and related supplies will be given priority.

U.S. officials plan to continue to monitor for side effects of the Pfizer vaccine among the health care workers and nursing homes who receive it, said Dr. Nancy Messonnier, director of the CDC’s National Center for Immunization and Respiratory Diseases, during the agency’s meeting on Thursday. The officers will use an SMS system called v-safe, which is designed to provide early warning of possible side effects of the vaccine.

During the meeting, FDA vaccine reviewer Dr. Susan Wollersheim found that the study data showed a “numerical imbalance” in Bell’s palsy, a condition that causes temporary weakness or paralysis of the muscles in the face. She said there were four cases in the vaccine group and none in the placebo group. Although the frequency of the cases was inconsistent with the general population, the FDA recommended further monitoring once the vaccine becomes more widely distributed.

Read the full letter from the FDA below:

Categories
Business

Pfizer’s Covid Vaccine and Allergic reactions: How Involved Ought to You Be?

Pfizer's Covid Vaccine and Allergies: How Concerned Should You Be?

Dr. Fauci acknowledged that the problem could affect many people.

“That’s one of the reasons it’s important to cover the waterfront with different vaccine platforms,” ​​he said, adding, “When we actually find out that there is a consistent problem with a certain subset of people like people with allergic reactions, You will always have other vaccine platforms to use and hopefully you won’t see that with those other platforms. “

Dr. Paul Offit, a vaccines expert at Philadelphia Children’s Hospital, said the initial, sweeping recommendation in the UK to mention severe allergic reactions was an overreaction that could unnecessarily discourage many people from a much-needed vaccine in the midst of a raging pandemic.

Millions of people in the United States are allergic to foods such as eggs or peanuts, as well as drugs or bee stings, and have had reactions so severe that doctors advised them to wear adrenaline injectors. But that doesn’t necessarily mean the vaccine is risky for them, he said. According to the National Institute of Allergy and Infectious Diseases, about five percent of children and four percent of adults in the United States have food allergies.

Less than 1 in a million recipients of other vaccines each year in the U.S. has an anaphylactic reaction, said Dr. Offit.

These reactions are treatable and much easier to control than a severe case of Covid-19, he said.

Many people with allergies to food, bee stings, or medication have received multiple vaccines without any problems.

The road to a coronavirus vaccine ›

Answers to your vaccine questions

As the coronavirus vaccine nears U.S. approval, here are some questions you may be wondering about:

    • If I live in the US, when can I get the vaccine? While the exact order of vaccine recipients may vary from state to state, most doctors and residents of long-term care facilities will come first. If you want to understand how this decision is made, this article will help.
    • When can I get back to normal life after the vaccination? Life will only get back to normal once society as a whole receives adequate protection against the coronavirus. Once countries have approved a vaccine, they can only vaccinate a few percent of their citizens in the first few months. The unvaccinated majority remain susceptible to infection. A growing number of coronavirus vaccines show robust protection against disease. However, it is also possible that people spread the virus without knowing they are infected because they have mild symptoms or no symptoms at all. Scientists don’t yet know whether the vaccines will also block the transmission of the coronavirus. Even vaccinated people have to wear masks for the time being, avoid the crowds indoors and so on. Once enough people are vaccinated, it becomes very difficult for the coronavirus to find people at risk to become infected. Depending on how quickly we as a society achieve this goal, life could approach a normal state in autumn 2021.
    • Do I still have to wear a mask after the vaccination? Yeah, but not forever. The two vaccines that may be approved this month clearly protect people from contracting Covid-19. However, the clinical trials that produced these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected with the coronavirus can spread it without experiencing a cough or other symptoms. Researchers will study this question intensively when the vaccines are introduced. In the meantime, self-vaccinated people need to think of themselves as potential spreaders.
    • Will it hurt What are the side effects? The vaccine against Pfizer and BioNTech, like other typical vaccines, is delivered as a shot in the arm. The injection is no different from the ones you received before. Tens of thousands of people have already received the vaccines, and none of them have reported serious health problems. However, some of them have experienced short-lived symptoms, including pain and flu-like symptoms that usually last a day. It is possible that people will have to plan to take a day off or go to school after the second shot. While these experiences are not pleasant, they are a good sign: they are the result of your own immune system’s encounter with the vaccine and a strong response that ensures lasting immunity.
    • Will mRNA vaccines change my genes? No. Moderna and Pfizer vaccines use a genetic molecule to boost the immune system. This molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse with a cell, allowing the molecule to slide inside. The cell uses the mRNA to make proteins from the coronavirus that can stimulate the immune system. At any given moment, each of our cells can contain hundreds of thousands of mRNA molecules that they produce to make their own proteins. As soon as these proteins are made, our cells use special enzymes to break down the mRNA. The mRNA molecules that our cells make can only survive a few minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a little longer, so the cells can make extra viral proteins and trigger a stronger immune response. However, the mRNA can hold for a few days at most before it is destroyed.

As a member of the FDA advisory board that met on Thursday, Dr. Offit for approval of the Pfizer vaccine. However, during the panel’s discussion of allergic reactions, he said, “This problem will not die until we have better data.”

He said it should investigate whether any ingredient in the vaccine can cause allergic reactions and whether people with other allergies might be particularly sensitive to it.

Categories
Health

F.D.A. Panel Provides Inexperienced Mild to Pfizer’s Covid Vaccine

F.D.A. Panel Gives Green Light to Pfizer's Covid Vaccine

Pfizer’s Covid-19 vaccine passed a critical milestone on Thursday when a panel of experts formally recommended that the Food and Drug Administration authorize the vaccine. The agency is likely to do so within days, giving health care workers and nursing home residents first priority to begin receiving the first shots early next week.

The F.D.A.’s vaccine advisory panel, composed of independent scientific experts, infectious disease doctors and statisticians, voted 17 to 4, with one member abstaining, in favor of emergency authorization for people 16 and older. With rare exceptions, the F.D.A. follows the advice of its advisory panels.

With this formal blessing, the nation may finally begin to slow the spread of the virus just as infections and deaths surge, reaching a record of more than 3,000 daily deaths on Wednesday. The F.D.A. is expected to grant an emergency use authorization on Saturday, according to people familiar with the agency’s planning, though they cautioned that last-minute legal or bureaucratic requirements could push the announcement to Sunday or later.

The initial shipment of 6.4 million doses will leave warehouses within 24 hours of being cleared by the F.D.A., according to federal officials. About half of those doses will be sent across the country, and the other half will be reserved for the initial recipients to receive their second dose about three weeks later.

The arrival of the first vaccines is the beginning of a complex, monthslong distribution plan coordinated by federal and local health authorities, as well as large hospitals and pharmacy chains, that if successful, will help return a grieving and economically depressed country back to some semblance of normal, maybe by summer.

“With the high efficacy and good safety profile shown for our vaccine, and the pandemic essentially out of control, vaccine introduction is an urgent need,” Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer, said at the meeting.

The vote caps a whirlwind year for Pfizer and its German partner BioNTech, which began working on the vaccine 11 months ago, shattering all speed records for vaccine development, which typically takes years. It is also a triumph for the F.D.A., which has upheld its reputation as the world’s gold standard for drug reviews despite months of political pressure from President Trump, who has sought to tie his political fortunes to the success of a vaccine. The Pfizer vaccine has already been given to people in Bahrain and Britain, where it was authorized on Dec. 2. Canada approved it on Wednesday.

The U.S. authorization of Pfizer’s vaccine is expected to be followed soon by one for Moderna’s version, which uses similar technology and has also shown promising results in clinical trials. Operation Warp Speed, the Trump administration’s multi-billion-dollar program to fast-track vaccine development, pre-ordered 100 million doses of Pfizer’s vaccine in July and heavily backed the development and manufacturing of Moderna’s vaccine.

More than 100 F.D.A. employees have worked nearly round the clock to review the application Pfizer submitted on Nov. 20, compressing months of analysis into weeks as they pored over thousands of pages of clinical trial and manufacturing data.

Earlier this week, career scientists at the F.D.A. published an analysis showing the vaccine worked across a variety of demographic groups and that it was somewhat effective even after the first of two doses.

During the daylong meeting on Thursday, panel members peppered company and agency experts with detailed questions about the safety and efficacy of the vaccine, which was found to be 95 percent effective in a late-stage clinical trial. Some members expressed concern that there was not enough data from 16- and 17-year-olds to know whether the vaccine would help them, but the committee decided the benefits for that group outweighed the risks.

Some members asked about the likelihood for serious allergic reactions, given the news that regulators in Britain recommended this week that people with a history of anaphylactic allergic reactions to medicines and foods not get the vaccine while they investigate two cases of allergic reactions among health care workers. Pfizer officials said there were no cases of serious allergic reactions in the trial of 44,000 participants. People with a history of allergic reactions to vaccines were excluded from the study.

One of the panel members, Dr. Paul Offit of the Children’s Hospital of Philadelphia, said he feared that statements by British regulators as well as remarks by Moncef Slaoui, a top U.S. vaccine official, could lead “tens of millions” of people with severe allergies to reject the vaccine even though evidence of a link to the shots was unclear. He asked Pfizer to conduct a separate study of people with a history of severe allergies, because “this issue is not going to die until we have better data.”

The F.D.A. said that it had asked Pfizer to include allergic reactions in its safety tracking plan and would include a warning in its instructions on the use of the vaccine.

One of the most hotly contested issues was how the broad authorization of the vaccine might affect the continuing clinical trial. Some experts have argued that, ethically, trial volunteers who received a placebo should be offered the vaccine once it is authorized, but others worried that move could tarnish the long-term results of the trial.

During the public portion of the meeting, consumer and public health advocates largely pushed the agency to authorize the vaccine, noting the urgency of the pandemic. One speaker, who identified himself as Kermit Kubitz, noted that he had no conflicts of interest to declare except for “a lot of elderly relatives.”

“They need this vaccine yesterday,” he said.

But advocates also asked regulators to be transparent about potential safety issues and to closely track the vaccine once it becomes available. Several said such measures were necessary to reassure a public that is hesitant to take a new vaccine, particularly Black and Native American people who have historically been mistreated by the medical community. “Before authorization is granted, affected communities need to have confidence that the vaccine is safe and effective,” said Sarah Christopherson of the National Women’s Health Center.

By insisting that the advisory committee vote on any vaccine, regulators created a shield against White House pressure to approve a product before the presidential election. When the panelists met in October to discuss the F.D.A.’s guidelines for approving Covid-19 vaccines, they urged the agency to take its time and cautioned that rushing the process could risk missing vital safety data and further erode public trust.

The scene that played out on Thursday — in which outside experts spent hours engaging government officials in an intense but often highly technical discussion about vaccine science — did not always make for exciting viewing. But the circumstances were certainly dramatic, as the experts were being asked to carefully weigh the risks and benefits of the vaccine, even as the United States reached the grim milestone of recording more than 3,000 Covid deaths on Wednesday and as thousands of people in Britain had already received it.

The F.D.A. has struggled, internally and externally, to move fast on its vaccine and treatment deliberations in order to curb the deadly virus’s spread — but not so fast as to undermine public confidence. It was a thin line to walk, and not helped by the torrent of troubling accusations by Mr. Trump and his advisers that the agency was moving too slowly.

Just days before Pfizer submitted its application, the company sent an enormous tranche of manufacturing data to the F.D.A. — including materials on how it was scaling up production — leaving regulators scrambling to evaluate it in time for a possible authorization.

As part of its oversight, the F.D.A. also had teams review company production facilities and clinical trial sites, where they verified that records corresponded to the accounts Pfizer had submitted to federal regulators.

At the same time, regulators were evaluating an equally complex emergency authorization application submitted by Moderna, whose data will be examined publicly during another F.D.A. outside advisory meeting next week.

The Road to a Coronavirus Vaccine ›

Answers to Your Vaccine Questions

As the coronavirus vaccine get closer to U.S. authorization, here are some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. The two vaccines that will potentially get authorized this month clearly protect people from getting sick with Covid-19. But the clinical trials that delivered these results were not designed to determine whether vaccinated people could still spread the coronavirus without developing symptoms. That remains a possibility. We know that people who are naturally infected by the coronavirus can spread it while they’re not experiencing any cough or other symptoms. Researchers will be intensely studying this question as the vaccines roll out. In the meantime, even vaccinated people will need to think of themselves as possible spreaders.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection won’t be any different from ones you’ve gotten before. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. But some of them have felt short-lived discomfort, including aches and flu-like symptoms that typically last a day. It’s possible that people may need to plan to take a day off work or school after the second shot. While these experiences aren’t pleasant, they are a good sign: they are the result of your own immune system encountering the vaccine and mounting a potent response that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

Regulators sometimes received documents from the companies as late as midnight and worked through the Thanksgiving holiday. Dr. Peter Marks, the top vaccine regulator at the F.D.A., joked last week at an event hosted by the American Medical Association that his team ate turkey sandwiches while examining documents.

“Among all global regulators, we are the ones that actually don’t just look at the company’s tables. We actually get down and dirty and we look at the actual adverse event reports, the bad spelling errors that are made by physicians sometimes, et cetera,” he said at the event.

Dr. Stephen M. Hahn, the F.D.A. commissioner, kept a careful distance from the review, according to people familiar with it.

Dr. Hahn had caved to pressure earlier in the summer to authorize an old malaria drug, hydroxychloroquine, for use in Covid patients even though there was little evidence that it worked. That decision was reversed after the agency found the drug was unlikely to be effective in Covid patients and carried a risk of potentially dangerous side effects. And Dr. Hahn faced withering criticism from the scientific community after he exaggerated the benefits of another treatment, convalescent plasma, an error he later corrected.

Mr. Trump accused agency officials of being part of the “deep state” and hinted that a vaccine could come before “a very special day” — Election Day. The F.D.A.’s reputation appeared to be headed in the same direction as that of the Centers for Disease Control and Prevention, which was widely criticized for not standing up to the president.

But senior regulators — and eventually Dr. Hahn himself — pushed back. The agency’s top career officials published an opinion piece in USA Today, acknowledging that the F.D.A.’s integrity had been called into question and insisting that they would “follow the science” during the pandemic. The agency prevailed in a battle with the White House over imposing more stringent guidelines for companies developing Covid vaccines.

“In this sort of environment, where there has been so much pressure and concern, the process does provide an important check and balance,” said Dr. Jesse L. Goodman, who previously served as the F.D.A.’s chief scientist. Holding an open meeting also allows the public to “be sure that a broader scientific and clinical community is comfortable with the decision.”

On Tuesday, the president held a summit intended to showcase the administration’s role in developing a vaccine. “We are just days away from authorization from the F.D.A. and we’re pushing them hard,” Mr. Trump said at the event.

Many health care workers around the country are already raring to get the vaccine. Dr. Andrew Barros, a critical care physician in Charlottesville, Virginia, who is scheduled to get his Pfizer shot at 2:30 p.m. on Dec. 15, said he is “looking forward to having a sore arm and hopefully being one step closer to having Covid under control.”

Pfizer’s clinical trial will continue even after its vaccine is authorized by the F.D.A., and the company and F.D.A. will continue to watch for safety concerns.

Pfizer said on Thursday that it planned to apply for full approval in April of 2021, after the company had collected six months of safety data. At that point, Pfizer would be allowed to sell its vaccine directly to hospitals and other health care providers.

Carl Zimmer and Katherine J. Wu contributed reporting.

Categories
Business

Pfizer’s Vaccine Gives Sturdy Safety After First Dose

Pfizer’s Vaccine Offers Strong Protection After First Dose

WASHINGTON – The coronavirus vaccine, manufactured by Pfizer and BioNTech, offers strong protection against Covid-19 within about 10 days of the first dose. This emerges from documents released Tuesday by the Food and Drug Administration ahead of a meeting of their vaccine advisory group.

The result is one of several significant new results in the newsletters, which includes more than 100 pages of data analysis from the Agency and Pfizer. Last month Pfizer and BioNTech announced that their two-dose vaccine had a 95 percent effectiveness rate after two doses three weeks apart. The new analyzes show that protection starts much earlier.

In addition, the vaccine worked well regardless of the race, weight, or age of a volunteer. While no serious adverse events from the vaccine were identified in the study, many participants experienced pain, fever, and other side effects.

“This is what an A + certificate looks like for a vaccine,” said Akiko Iwasaki, an immunologist at Yale University.

On Thursday, the FDA’s Vaccine Advisory Panel will discuss these materials prior to a vote on whether to recommend approval of the vaccine by Pfizer and BioNTech.

Pfizer and BioNTech started a large-scale clinical trial in July that recruited 44,000 people in the US, Brazil and Argentina. Half of the volunteers received the vaccine and half the placebo.

New coronavirus cases in the vaccinated group of volunteers quickly subsided about 10 days after the first dose, according to a graphic in the educational materials. The number of cases increased steadily in the placebo group.

The vaccine’s swift action could benefit not only the people who receive it, but also the strained hospitals in the country, limiting the flow of new patients to intensive care units.

Despite the early protection provided by the first dose, it is unclear how long this protection would last on its own, which underscores the importance of the second dose. Previous studies have shown that the second dose of the Pfizer BioNTech vaccine gives the immune system a significant long-term boost that is seen with many other vaccines.

The effectiveness of the vaccine after the first dose, according to Dr. William C. Gruber, senior vice president of Pfizer Vaccine Clinical Research and Development, at about 52 percent. After the second dose, this value increases to about 95 percent. “Two doses of the vaccine offer maximum protection,” he said.

Many experts have raised concerns that the coronavirus vaccines might protect some people better than others. However, the results in the educational materials indicate no such problem. The vaccine has a high rate of effectiveness in both men and women, and similar rates in whites, blacks, and Latinos. It also worked well on obese people who are at higher risk of developing Covid-19.

Some vaccines for other diseases produce a weak immune response in older adults. However, Pfizer and BioNTech found that people over 65 received about as much protection from the coronavirus vaccine as younger people.

“I’ve never seen anything like it,” said Dr. Gregory Poland, a vaccine researcher at the Mayo Clinic, on the vaccine’s robust response in the overweight and elderly.

Even if the vaccine is approved by the FDA, the study will continue. In the briefing documents, the companies said they would encourage people to stay in the study for as long as possible without knowing whether they received the vaccine or the placebo, so the researchers can continue to gather information on whether the vaccine is safe and effective.

The road to a coronavirus vaccine

Interesting facts about vaccines

Confused by all of the technical terms used to describe how vaccines work and study? Let us help:

    • Adverse event: A health problem that occurs in volunteers in a clinical trial with a vaccine or drug. An adverse event is not always caused by the treatment tested in the study.
    • Antibody: A protein produced by the immune system that can attach to a pathogen such as the coronavirus and prevent it from infecting cells.
    • Approval, Licensing, and Approval for Emergency Use: Medicines, vaccines and medical devices cannot be sold in the US for no profit approval by the Food and Drug Administration, also known as Licensing. After a company submits the results of clinical studies to the FDA for review, the agency decides whether the product is safe and effective. This process usually takes many months. If the country faces an emergency – like a pandemic – a company can file an application instead Emergency approvalthat can be granted much faster.
    • Background rate: How often does the general population experience a health problem called an Adverse Event? To determine whether a vaccine or drug is safe, researchers compare the rate of adverse events in one study to the background rate.
    • Effectiveness: The benefit of a vaccine compared to a placebo, measured in a clinical trial. For example, to test a coronavirus vaccine, the researchers compare how many people in the vaccinated group and the placebo group are receiving Covid-19. In contrast, effectiveness is the benefit that a vaccine or drug offers in the real world. A vaccine’s effectiveness can be found to be less or more effective than its effectiveness.
    • Phases 1, 2 and 3 studies: Clinical trials typically take place in three phases. Phase 1 studies typically involve a few dozen people to determine whether a vaccine or drug is safe. In Phase 2 trials that involve hundreds of people, researchers can try different doses and take more measurements of the vaccine’s effects on the immune system. Phase 3 trials, involving thousands or tens of thousands of volunteers, determine the safety and effectiveness of the vaccine or medicine by waiting to see how many people are protected from the disease it is intended to be used against.
    • Placebo: A substance with no therapeutic effect that is widely used in clinical trials. For example, to see if a vaccine can prevent Covid-19, researchers can inject the vaccine into half of their volunteers while the other half are given a placebo with salt water. You can then compare how many people are infected in each group.
    • Post-market surveillance: The surveillance that occurs after a vaccine or drug has been approved and regularly prescribed by doctors. This monitoring usually confirms that the treatment is safe. Rarely, side effects are noted in certain groups of people that were overlooked during clinical trials.
    • Preclinical Research: Studies that take place prior to the start of a clinical trial typically include experiments that test a treatment on cells or animals.
    • Viral vector vaccines: A type of vaccine that uses a harmless virus to deliver immune-stimulating ingredients into the human body. Viral vectors are used in several experimental Covid-19 vaccines, including those developed by AstraZeneca and Johnson & Johnson. Both companies use a cold virus called adenovirus as a vector. The adenovirus carries coronavirus genes.
    • Test protocol: A series of procedures that must be performed during a clinical trial.

The educational materials also provide a deeper look into the safety of the vaccine. In any large clinical trial, some people who receive vaccines have health conditions unrelated to the vaccine itself. Comparing their symptom rates with those of the placebo group, as well as background rates in a population, may indicate symptoms that a vaccine may actually cause.

The FDA concluded that there were no “significant imbalances” between the two groups in serious health complications known as adverse events. The agency found that four people in the vaccinated group had a form of facial paralysis called Bell’s palsy, with no cases in the placebo group. The difference between the two groups was not significant and the rate in the vaccinated group was not significantly higher than in the general population.

The new Pfizer analysis found that many volunteers who received the vaccine felt sick in the hours after the second dose, suggesting that many people may need to request a day off or be willing to rest until symptoms appear ease up. Among the 16 to 55 year olds, more than half developed fatigue and more than half also reported headaches. Slightly more than a third experienced chills and 37 percent had muscle pain. About half of those over 55 felt tired, a third had a headache, and about a quarter felt chills, while 29 percent had muscle pain.

“Taking a day off after the second dose is a good thing to anticipate,” said Dr. Iwasaki.

On Monday, Kristen Choi, a psychiatric nurse and health care researcher at the University of California at Los Angeles, released a firsthand report on the symptoms she experienced as a participant in the Pfizer BioNTech study, including chills, nausea and headaches and fever.

“Doctors need to be prepared to discuss with patients why they should trust the vaccine and that its adverse effects could be very similar to Covid-19,” wrote Dr. Choi in JAMA Internal Medicine. She advised doctors to tell patients that these uncomfortable symptoms “are a sign that the vaccine is working despite the unfortunate similarities with the symptoms of the disease”.